Delivery Order SPE2DB22D3004-SPE2DB25FRV02
- Not listed
- The Defense Logistics Agency awarded a $1,994.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3mL insulin pens, with an ultimate completion date of September 3, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of NovoLog Mix 70/30 FlexPen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order has a ceiling value of $1,342.84 with an ultimate completion date of September 8, 2025. The contract represents a non-set-aside procurement issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,396.34 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3ml insulin pens. This is a firm fixed-price, non-set-aside contract with a completion date of September 10, 2025, and performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX,...
- The Defense Logistics Agency awarded a $1,003.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 28, 2025. This contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle active through December 2026. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,632.10 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 22, 2025. This competitive award (no set-aside used) utilizes a firm fixed price structure and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $1,725.61 to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ml insulin pens on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,562.48 to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3mL insulin pens. This is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and operations. This...
- The Defense Logistics Agency awarded a $3,791.46 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3mL insulin pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 18, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The pharmaceutical product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,217.78 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog Mix 70-30 FlexPen 3ml insulin pens. This is a firm fixed price, competitively awarded contract with a completion date of July 21, 2025, and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRV02Delivery Order
The Defense Logistics Agency awarded a $1,003.70 firm fixed price delivery order to AmerisourceBergen Drug Corp for NovoLog Mix 70-30 FlexPen 3ML insulin pens, with an ultimate completion date of August 5, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical supply vehicle running through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and supplies military and veteran healthcare systems with a broad range of medications and medical supplies. This delivery order for diabetes management medication exemplifies AmerisourceBergen's role as a primary pharmaceutical provider within the DLA's Medical Supply Chain. The company maintains consistent access to federal procurement through its substantial prime contract vehicle, which enables it to fulfill medical supply requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The order demonstrates the company's capability to meet both routine pharmaceutical needs and specialized medical commodities supporting military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/4/25 |